Epigenetic reprogramming and imprinting in origins of disease - PubMed (original) (raw)
Review
Epigenetic reprogramming and imprinting in origins of disease
Wan-yee Tang et al. Rev Endocr Metab Disord. 2007 Jun.
Abstract
The traditional view that gene and environment interactions control disease susceptibility can now be expanded to include epigenetic reprogramming as a key determinant of origins of human disease. Currently, epigenetics is defined as heritable changes in gene expression that do not alter DNA sequence but are mitotically and transgenerationally inheritable. Epigenetic reprogramming is the process by which an organism's genotype interacts with the environment to produce its phenotype and provides a framework for explaining individual variations and the uniqueness of cells, tissues, or organs despite identical genetic information. The main epigenetic mediators are histone modification, DNA methylation, and non-coding RNAs. They regulate crucial cellular functions such as genome stability, X-chromosome inactivation, gene imprinting, and reprogramming of non-imprinting genes, and work on developmental plasticity such that exposures to endogenous or exogenous factors during critical periods permanently alter the structure or function of specific organ systems. Developmental epigenetics is believed to establish "adaptive" phenotypes to meet the demands of the later-life environment. Resulting phenotypes that match predicted later-life demands will promote health, while a high degree of mismatch will impede adaptability to later-life challenges and elevate disease risk. The rapid introduction of synthetic chemicals, medical interventions, environmental pollutants, and lifestyle choices, may result in conflict with the programmed adaptive changes made during early development, and explain the alarming increases in some diseases. The recent identification of a significant number of epigenetically regulated genes in various model systems has prepared the field to take on the challenge of characterizing distinct epigenomes related to various diseases. Improvements in human health could then be redirected from curative care to personalized, preventive medicine based, in part, on epigenetic markings etched in the "margins" of one's genetic make-up.
Figures
Fig. 1
Schematic diagram of our hypothesis on how neonatal estrogen (E2) and bisphenol A (BPA) alter the prostate genome via DNA methylation and histone modifications with phosphodiesterase type 4 variant 4 (PDE4D4) used as an example. Without exposure to E2 and BPA, PDE4D4 is silenced with aging. A group of enzymes, including histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and methylated DNA-binding protein (MeCP2), may be involved in gene silencing. Nevertheless, after exposure to E2 and BPA, PDE4D4 fails to “shut-off” and is actively transcribed throughout life. We propose that chromatin structure is remodeled by opening the chromatin in the presence of histone acetyltransferase (HAT), methylation binding domains (MBDs) and other unknown factors and that this remodeling further prevents HDACs, DNMTs, and MeCP2 from binding to silence the gene. Persistent elevation of PDE4D4 expression is associated with the increase in incidence of prostate cancer later in life
Similar articles
- Epigenetic control.
Delcuve GP, Rastegar M, Davie JR. Delcuve GP, et al. J Cell Physiol. 2009 May;219(2):243-50. doi: 10.1002/jcp.21678. J Cell Physiol. 2009. PMID: 19127539 Review. - The epigenetics of oral cancer.
Shaw R. Shaw R. Int J Oral Maxillofac Surg. 2006 Feb;35(2):101-8. doi: 10.1016/j.ijom.2005.06.014. Epub 2005 Sep 8. Int J Oral Maxillofac Surg. 2006. PMID: 16154320 Review. - Developmental origin of chronic diseases: toxicological implication.
Bezek S, Ujházy E, Mach M, Navarová J, Dubovický M. Bezek S, et al. Interdiscip Toxicol. 2008 Jun;1(1):29-31. doi: 10.2478/v10102-010-0029-8. Interdiscip Toxicol. 2008. PMID: 21218103 Free PMC article. - Critical periods and the developmental origins of disease: an epigenetic perspective of schizophrenia.
Perrin M, Kleinhaus K, Messinger J, Malaspina D. Perrin M, et al. Ann N Y Acad Sci. 2010 Sep;1204 Suppl(0):E8-13. doi: 10.1111/j.1749-6632.2010.05644.x. Ann N Y Acad Sci. 2010. PMID: 20840164 Free PMC article. - Epigenetics: what is it and why is it important to mental disease?
Isles AR, Wilkinson LS. Isles AR, et al. Br Med Bull. 2008;85:35-45. doi: 10.1093/bmb/ldn004. Epub 2008 Feb 15. Br Med Bull. 2008. PMID: 18281695 Review.
Cited by
- Nitric oxide: perspectives and emerging studies of a well known cytotoxin.
Paradise WA, Vesper BJ, Goel A, Waltonen JD, Altman KW, Haines GK, Radosevich JA. Paradise WA, et al. Int J Mol Sci. 2010 Jul 16;11(7):2715-45. doi: 10.3390/ijms11072715. Int J Mol Sci. 2010. PMID: 20717533 Free PMC article. Review. - Environmental epigenetics and allergic diseases: recent advances.
Kuriakose JS, Miller RL. Kuriakose JS, et al. Clin Exp Allergy. 2010 Nov;40(11):1602-10. doi: 10.1111/j.1365-2222.2010.03599.x. Epub 2010 Aug 16. Clin Exp Allergy. 2010. PMID: 20718778 Free PMC article. Review. - Urinary bisphenol A and type-2 diabetes in U.S. adults: data from NHANES 2003-2008.
Silver MK, O'Neill MS, Sowers MR, Park SK. Silver MK, et al. PLoS One. 2011;6(10):e26868. doi: 10.1371/journal.pone.0026868. Epub 2011 Oct 26. PLoS One. 2011. PMID: 22046388 Free PMC article. - Endocrine disrupting chemicals and disease susceptibility.
Schug TT, Janesick A, Blumberg B, Heindel JJ. Schug TT, et al. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):204-15. doi: 10.1016/j.jsbmb.2011.08.007. Epub 2011 Aug 27. J Steroid Biochem Mol Biol. 2011. PMID: 21899826 Free PMC article. Review. - Hypomethylation of dual specificity phosphatase 22 promoter correlates with duration of service in firefighters and is inducible by low-dose benzo[a]pyrene.
Ouyang B, Baxter CS, Lam HM, Yeramaneni S, Levin L, Haynes E, Ho SM. Ouyang B, et al. J Occup Environ Med. 2012 Jul;54(7):774-80. doi: 10.1097/JOM.0b013e31825296bc. J Occup Environ Med. 2012. PMID: 22796920 Free PMC article.
References
- Liu Y, Freedman BI. Genetics of progressive renal failure in diabetic kidney disease. Kidney Int. 2005;(Suppl):S94–7. - PubMed
- Kroll TG. Molecular events in follicular thyroid tumors. Cancer Treat Res. 2004;122:85–105. - PubMed
- Moore MA. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol. 2005;33:719–37. - PubMed
- Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–61. - PubMed
- Tusie Luna MT. Genes and type 2 diabetes mellitus. Arch Med Res. 2005;36:210–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 ES015905/ES/NIEHS NIH HHS/United States
- ES15584/ES/NIEHS NIH HHS/United States
- R21 ES012281/ES/NIEHS NIH HHS/United States
- R01 ES015584/ES/NIEHS NIH HHS/United States
- ES15905/ES/NIEHS NIH HHS/United States
- ES12281/ES/NIEHS NIH HHS/United States
- P30 ES006096/ES/NIEHS NIH HHS/United States
- R21 ES013071/ES/NIEHS NIH HHS/United States
- ES13071/ES/NIEHS NIH HHS/United States
- K99 ES016817/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources